

CITATION REPORT

List of articles citing

Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy

DOI: 10.1038/sj.ijir.3900815

International Journal of Impotence Research, 2002, 14, 50-3.

Source: <https://exaly.com/paper-pdf/33686396/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
52	Current oral treatments for erectile dysfunction. <i>Expert Opinion on Pharmacotherapy</i> , 2002 , 3, 1613-29	4	8
51	Viability and safety of combination drug therapies for erectile dysfunction. <i>Journal of Urology</i> , 2003 , 170, S20-3; discussion S23	2.5	23
50	Sildenafil in erectile dysfunction: a critical review. <i>Current Medical Research and Opinion</i> , 2003 , 19, 241-62.	2.5	77
49	Oral agents for erectile dysfunction. <i>British Journal of Hospital Medicine</i> , 2003 , 64, 292-5		
48	Preliminary observations on the use of propionyl-L-carnitine in combination with sildenafil in patients with erectile dysfunction and diabetes. <i>Current Medical Research and Opinion</i> , 2004 , 20, 1377-84.	2.5	30
47	Future options for combination therapy in the management of erectile dysfunction in older men. <i>Drugs and Aging</i> , 2004 , 21, 555-64	4.7	26
46	Treatment Options for Erectile Dysfunction in Patients Failing Oral Drug Therapy. <i>EAU Update Series</i> , 2004 , 2, 75-83		11
45	[Combination therapy in benign prostatic hyperplasia (BPH)]. <i>Annales D'Urologie</i> , 2004 , 38 Suppl 2, S24-8		2
44	Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil. <i>Journal of Andrology</i> , 2004 , 25, 625-9		42
43	Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction. <i>BJU International</i> , 2005 , 95, 103-9; discussion 109	5.6	55
42	Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system. <i>BJU International</i> , 2005 , 95 Suppl 4, 19-28	5.6	39
41	Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 75-84	4	43
40	Safety and tolerability of oral erectile dysfunction treatments in the elderly. <i>Drugs and Aging</i> , 2005 , 22, 323-38	4.7	5
39	Effect of doxazosin with and without rho-kinase inhibitor on human corpus cavernosum smooth muscle in the presence of bladder outlet obstruction. <i>Journal of Urology</i> , 2006 , 175, 2345-9	2.5	20
38	Effects of alpha(1)-adrenoceptor antagonists on male sexual function. <i>Drugs</i> , 2006 , 66, 287-301	12.1	95
37	Vasodilatory factors in treatment of older men with symptomatic benign prostatic hyperplasia. <i>Urology</i> , 2006 , 67, 225-31	1.6	7
36	Management of sildenafil treatment failures. <i>Current Opinion in Urology</i> , 2006 , 16, 449-59	2.8	33

35	Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice. <i>Andrologia</i> , 2006 , 38, 1-12	2.4	55
34	Beneficial effects of extended-release doxazosin and doxazosin standard on sexual health. <i>BJU International</i> , 2006 , 97, 559-66	5.6	23
33	Treating erectile dysfunction when PDE5 inhibitors fail. <i>BMJ, The</i> , 2006 , 332, 589-92	5.9	82
32	The management of phosphodiesterase-5 (PDE5) inhibitor failure. <i>Current Vascular Pharmacology</i> , 2006 , 4, 89-93	3.3	29
31	Medical treatment of benign prostatic hyperplasia. <i>Postgraduate Medical Journal</i> , 2007 , 83, 73-8	2	4
30	Serotonin induces a biphasic response in rabbit cavernosal smooth muscle: relevance to the erectile process. <i>Urologia Internationalis</i> , 2007 , 79, 255-61	1.9	5
29	Treating coexistent benign prostatic hyperplasia/lower urinary tract symptoms and erectile dysfunction in the aging male. <i>Aging Health</i> , 2007 , 3, 191-200		
28	Erectile dysfunction as the presenting symptom of a pheochromocytoma. <i>European Journal of Internal Medicine</i> , 2007 , 18, 593-4	3.9	2
27	Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. <i>European Urology</i> , 2007 , 51, 1717-23	10.2	177
26	Common approach to managing lower urinary tract symptoms and erectile dysfunction. <i>Asian Journal of Andrology</i> , 2008 , 10, 45-53	2.8	15
25	Combination of alfuzosin and tadalafil exerts in vitro an additive relaxant effect on human corpus cavernosum. <i>Journal of Sexual Medicine</i> , 2008 , 5, 935-945	1.1	23
24	Los problemas de erección tienen solución. <i>Revista Internacional De Andrología</i> , 2008 , 6, 161-168	0.6	1
23	Effect of vardenafil on blood pressure profile of patients with erectile dysfunction concomitantly treated with doxazosin gastrointestinal therapeutic system for benign prostatic hyperplasia. <i>Journal of Urology</i> , 2008 , 180, 1042-6	2.5	17
22	Non-invasive management of primary phosphodiesterase type 5 inhibitor failure in patients with erectile dysfunction. <i>Therapeutic Advances in Urology</i> , 2009 , 1, 235-42	3.2	7
21	Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. <i>Journal of Sexual Medicine</i> , 2009 , 6, 544-52	1.1	89
20	Combination of doxazosin and sildenafil exerts an additive relaxing effect compared with each compound alone on human cavernosal and prostatic tissue. <i>Journal of Sexual Medicine</i> , 2009 , 6, 836-47	1.1	33
19	Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. <i>International Journal of Clinical Practice</i> , 2010 , 64, 240-55	2.9	119
18	Combination of alfuzosin and tadalafil exerts an additive relaxant effect on human detrusor and prostatic tissues in vitro. <i>European Urology</i> , 2010 , 57, 699-707	10.2	28

17	Clinical Andrology. 2010 ,			1
16	Medical management of benign prostatic hyperplasia in the light of available evidence. <i>Turk Uroloji Dergisi</i> , 2010 , 36, 418-429			
15	Phosphodiesterase Type 5 Inhibitors for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia. <i>Urological Science</i> , 2010 , 21, 2-7	0.3		
14	Will Medical Management of Benign Prostatic Hyperplasia Result in Better or Worse Sexual Function in Men?. <i>Urological Science</i> , 2011 , 22, 14-18	0.3	1	
13	The effects of the combined use of a PDE5 inhibitor and medications for hypertension, lower urinary tract symptoms and dyslipidemia on corporal tissue tone. <i>International Journal of Impotence Research</i> , 2012 , 24, 221-7	2.3	5	
12	Effect of patient-optimized doses of tamsulosin on erectile function in men with erectile dysfunction and lower urinary tract symptoms. <i>Korean Journal of Urology</i> , 2013 , 54, 100-5			5
11	Nonresponse to PDE5 inhibitors in erectile dysfunction. Part 2. <i>Human Andrology</i> , 2014 , 4, 45-53	1		
10	A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. <i>Journal of Sexual Medicine</i> , 2014 , 11, 187-96	1.1	51	
9	The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis. <i>Journal of Sexual Medicine</i> , 2014 , 11, 1539-45	1.1	34	
8	Sexual Dysfunction Related to Drugs: a Critical Review. Part V: α -Blocker and 5-ARI Drugs. <i>Pharmacopsychiatry</i> , 2016 , 49, 3-13	2	29	
7	Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails. <i>Drugs and Aging</i> , 2018 , 35, 175-187	4.7	12	
6	Unreliability of the Duplex Scan in Diagnosing Corporal Venous Occlusive Disease in Young Healthy Men With Erectile Deficiency. <i>Urology</i> , 2018 , 113, 91-98	1.6	7	
5	Sexual Dysfunctions Related to Drugs Used in the Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Narrative Review on α -Blockers and 5-Alpha Reductase Inhibitors. <i>Uro</i> , 2021 , 1, 82-98			
4	An open, comparative, multicentre clinical study of combined oral therapy with sildenafil and doxazosin GITS for treating Chinese patients with erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia. <i>Asian Journal of Andrology</i> , 2011 , 13, 630-5	2.8	16	
3	Combination therapy for erectile dysfunction: an update review. <i>Asian Journal of Andrology</i> , 2011 , 13, 382-90	2.8	24	
2	Study of phosphodiesterase 5 inhibitors and α -adrenoceptor antagonists used alone or in combination for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020 , 72, 13-21	4.4	9	
1	Extending the rationale of combination therapy to unresponsive erectile dysfunction. <i>Reviews in Urology</i> , 2007 , 9, 197-206	1	6	